Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Partially revisedKey initiatives
01Include the development plan for H-1337
Plan assumptionsThe above plan is based on the development plan assumed by the licensing partner or the Company's projections and may differ from actual development progress.
Non-financial targetsIndicator name Development progress for H-1337 (glaucoma treatment, Japan) / Target value Small-scale dose-confirmation study, start of Phase 3 / Timing 2028, 2029 onward
Risks identified by the company
The above plan is based on the development plan assumed by the licensing partner or the Company's projections and may differ from actual development progress.
Reason for revision or withdrawal
As stated in the "Notice Concerning the Determination of the Domestic Development Plan for the Glaucoma Treatment H-1337" disclosed today, the development plan for H-1337 has been included.
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Plan period | 2025–2028 (H-1337: 2029–start of Phase 3) |
| Progress against the plan | Partially revised |
| Non-financial targets | Indicator name Development progress for H-1337 (glaucoma treatment, Japan) / Target value Small-scale dose-confirmation study, start of Phase 3 / Timing 2028, 2029 onward |
| Plan assumptions | The above plan is based on the development plan assumed by the licensing partner or the Company's projections and may differ from actual development progress. |
| Key initiatives | Include the development plan for H-1337 |
| Reason for revision or withdrawal | As stated in the "Notice Concerning the Determination of the Domestic Development Plan for the Glaucoma Treatment H-1337" disclosed today, the development plan for H-1337 has been included. |
| Risks identified | The above plan is based on the development plan assumed by the licensing partner or the Company's projections and may differ from actual development progress. |
| Publication date | 3 September 2026 |
Items this document does not state (16)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetResults under the previous planSize of the Target MarketDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The development plan for H-1337 was included based on the "Notice Concerning the Determination of the Domestic Development Plan for the Glaucoma Treatment H-1337" disclosed today.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.